PRMT5 regulates m6A demethylation of ALKBH5 to promote doxorubicin sensitivity in breast cancer.[48] PRMT1 methylates WTAP and promotes multiple myeloma tumorigenesis by m6A modification of NDUFS6.[49] In addition, PRMT5 inhibits ferroptosis by methylating KEAP1 in triple‐negative breast cancer, and PRMT9 suppresses ferroptosis by methylating HSPA8 in hepatocellular cancer.[50, 51] There are complicated interaction networks in tumors, but this study mainly focuses on the PRMT3‐METTL14‐GPX4 regulatory axis in EC. Here, KEAP1 is linked to hepatocellular carcinoma.